Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus PANTOPRAZOLE SODIUM IN 0 9 SODIUM CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus PANTOPRAZOLE SODIUM IN 0 9 SODIUM CHLORIDE.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
40 mg intravenously over 2-15 minutes once daily for up to 10 days.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Approximately 1 hour (range 0.5–2 hours) in healthy adults; prolonged in hepatic impairment (up to 3–6 hours) and CYP2C19 poor metabolizers.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Renal: approximately 80% as metabolites and unchanged drug; fecal: approximately 20% as metabolites.
Category C
Category A/B
Electrolyte
Electrolyte